indirubin has been researched along with imatinib mesylate in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Hou, M; Ji, C; Li, L; Ma, D; Sun, J; Yan, S; Zhang, M | 1 |
| Bhatia, R; Chen, W; Cheng, X; Eisenbrand, G; Jove, R; Konig, H; Merz, KH; Nam, S; Park, S; Scuto, A; Yang, F; Yoo, HS | 1 |
| Gaboriaud-Kolar, N; Gerolymatos, P; Horne, DA; Jove, R; Mikros, E; Myrianthopoulos, V; Nam, S; Skaltsounis, AL; Vougogiannopoulou, K | 1 |
| Gao, C; Li, H; Liu, C; Liu, G; Liu, L; Sun, C; Yang, J; Zhou, C; Zhuang, J | 1 |
4 other study(ies) available for indirubin and imatinib mesylate
| Article | Year |
|---|---|
Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
Topics: Adult; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction | 2010 |
Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling.
Topics: Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Survival; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Humans; Imatinib Mesylate; Immunoprecipitation; Indoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oximes; Piperazines; Pyridones; Pyrimidines; Signal Transduction; STAT5 Transcription Factor | 2012 |
Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases | 2016 |
Deciphering the mechanism of Indirubin and its derivatives in the inhibition of Imatinib resistance using a "drug target prediction-gene microarray analysis-protein network construction" strategy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Databases, Factual; Down-Regulation; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Indoles; Molecular Dynamics Simulation; Oligonucleotide Array Sequence Analysis; Protein Interaction Mapping | 2019 |